北 京 大 成 律 师 事 务 所 关 于 北 京 同 仁 堂 股 份 有 限 公 司 2025 年 第 三 次 临 时 股 东 会 的 法 律 意 见 书 大成证字[2025]第 227 号 北 京 大 成 律 师 事 务 所 www.dentons.cn 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16-21 层（100020） ZT International Center, No.10, Chaoyangmen Nandajie, Dongdaqiao Road Chaoyang District, 100020, Beijing, China Tel:+8610-58137799 Fax:+8610-58137788 北京大成律师事务所 关于北京同仁堂股份有限公司 2025 年第三次临时股东会的法律意见书 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责的精神，对本次股东会所涉及的有关事项和相关文件进行了 必要的核查和验证，出席了本次股东会，出具法律意见如下： 一、本次股东会的召集、召开的程序 （一）本次股东会的召集程序 本次股东会由董事会提议并召 ...

Core Insights - Tong Ren Tang Group's subsidiary, Tong Ren Tang Medical and Health, is undergoing a listing hearing on the Hong Kong Stock Exchange, with CICC as the sponsor [1] - In the first five months of this year, Tong Ren Tang Medical and Health reported revenue of 477 million yuan, a year-on-year increase of 6.1%, and a net profit of 10.04 million yuan, up 146% year-on-year [1] - If successfully listed, Tong Ren Tang Medical and Health will become the fourth publicly listed company under Tong Ren Tang Group, joining Tong Ren Tang Co., Ltd., Tong Ren Tang Technology, and Tong Ren Tang Guoyao [1] Company Overview - Tong Ren Tang Medical and Health focuses on traditional Chinese medical services, operating 12 owned medical institutions and one internet hospital, while also managing 10 offline medical institutions [1] - Other subsidiaries of Tong Ren Tang Group primarily engage in the production and sale of traditional Chinese health products, providing limited medical services such as in-store consultations by traditional Chinese medicine practitioners [1] - Tong Ren Tang Medical and Health distinguishes itself from other group members in terms of scale, positioning, service scope, and target customers, thus not considering itself a significant competitor to the group's overall business [1] Shareholding Structure - Tong Ren Tang Group holds approximately 84% of the shares in Tong Ren Tang Medical and Health, with the remaining shares owned by investors such as Bozhou Yipin De, Jining Yinling, and Bingrong Investment [1]

Core Insights - The article discusses the ongoing initiatives of the "Party Building and Industry Innovation Joint Construction Mechanism" (referred to as "Party Building Joint Construction") in Beijing, emphasizing its role in enhancing industrial collaboration and public services [1][2][5] Group 1: Party Building Joint Construction Activities - The Party Building Joint Construction has expanded its activities into enterprises, campuses, and communities, demonstrating a commitment to high-quality development through high-quality party building [1][4] - In September, the initiative hosted a series of events, including a traditional Chinese medicine cultural festival and a campus integration event, which collectively served over 2,000 residents [2][4] - The activities included health services, product showcases, and job recruitment, effectively bridging the gap between industry needs and community services [3][4] Group 2: Collaboration with Educational Institutions - The partnership with Beijing Technology and Business University marks a significant step in integrating education with industry, establishing a framework for long-term collaboration [3][5] - The signing of a joint construction agreement aims to enhance the connection between education, talent development, and industry needs, fostering a collaborative ecosystem [3][5] - The campus market event featured over 40 booths offering health consultations, product sales, and employment information, showcasing the tangible benefits of the collaboration [3][4] Group 3: Societal Impact and Future Directions - The initiative reflects a dual empowerment model where enterprises provide quality products and services while local governments support business development, enhancing community well-being [5][6] - The Party Building Joint Construction is positioned to continue expanding its reach, aiming for a regularized approach to integrating health knowledge, quality products, and job opportunities into various sectors [6] - This model not only addresses the challenges of integrating party building with business operations but also supports the development of new productive forces, contributing to both economic and social benefits [6]

Core Viewpoint - Beijing Tongrentang Medical Investment Co., Ltd. (Tongrentang Medical) is focusing on traditional Chinese medicine (TCM) healthcare services and has passed the listing hearing on the Hong Kong Stock Exchange, with CICC as its sole sponsor [1]. Company Overview - Tongrentang Medical is a subsidiary of the Tongrentang Group, strategically focused on providing comprehensive TCM healthcare services to individual clients and standardized management services to institutional clients, along with various pharmaceutical and other products [5]. - The company combines "medicine" and "nurturing" to offer modern and customized TCM healthcare services [5]. - As of September 23, 2025, the company has established a tiered TCM healthcare service network, including 12 self-owned offline medical institutions and one internet hospital, as well as 10 offline managed medical institutions [5]. Market Position - By total outpatient and inpatient visits in 2024, Tongrentang Medical is the largest private TCM hospital group in China, holding a market share of 1.7%. By total medical service revenue in 2024, it ranks second in the private TCM hospital sector with a market share of 0.2%, capturing 46.5% of the total market size of TCM healthcare services in China for that year [5]. Revenue Growth - Revenue from TCM healthcare services increased from RMB 815 million in the year ending December 31, 2022, to RMB 995 million in the year ending December 31, 2023, representing a growth of 22.1%. Revenue from management services surged from RMB 1.9 million to RMB 9.6 million during the same period. Revenue from health products and other products rose by 57.0%, from RMB 87.7 million to RMB 138 million [6]. Financial Performance - The company reported revenues of approximately RMB 911 million, RMB 1.15 billion, RMB 1.18 billion, and RMB 477 million for the years 2022, 2023, 2024, and the five months ending May 31, 2025, respectively. The corresponding profits (losses) were -RMB 9.23 million, RMB 42.63 million, RMB 46.2 million, and RMB 13.06 million [7][8].

Core Viewpoint - Beijing Tongrentang Healthcare Investment Co., Ltd. (Tongrentang Healthcare) is preparing for an IPO on the Hong Kong Stock Exchange, with CICC as its sole sponsor [1]. Company Overview - Tongrentang Healthcare is a subsidiary of Tongrentang, focusing on traditional Chinese medicine (TCM) healthcare services, providing comprehensive TCM medical services to individual clients and standardized management services to institutional clients [5][6]. - The company combines "medicine" and "nurturing," offering modern and customized TCM healthcare services [5]. Market Position - As of September 23, 2025, the company has established a tiered TCM healthcare service network, including 12 self-owned offline medical institutions and one internet hospital, along with 10 offline managed medical institutions [5]. - By 2024, Tongrentang Healthcare is the largest non-public TCM hospital group in China by outpatient and inpatient visits, holding a market share of 1.7%. It ranks second in the non-public TCM healthcare service industry by total medical service revenue, with a market share of 0.2%, capturing 46.5% of the total market size of the TCM healthcare industry in China [5]. Financial Performance - Revenue from TCM medical services increased from RMB 815 million in 2022 to RMB 995 million in 2023, representing a growth of 22.1%. Revenue from management services surged from RMB 1.9 million to RMB 9.6 million, while revenue from health products and other products rose by 57.0% from RMB 87.7 million to RMB 138 million during the same period [6]. - The company's revenue for the fiscal years 2022, 2023, 2024, and the first five months of 2025 was approximately RMB 911 million, RMB 1.153 billion, RMB 1.175 billion, and RMB 477 million, respectively. The corresponding net profits were -RMB 9.23 million, RMB 42.63 million, RMB 46.2 million, and RMB 13.06 million [7][8].

Group 1 - Beijing Tongrentang Medical Investment Co., Ltd. has updated its post-hearing information package, indicating that the Hong Kong Stock Exchange has approved its IPO hearing [1]

证券代码：600085 证券简称：同仁堂 公告编号：2025-033 北京同仁堂股份有限公司 关于控股子公司签署日常关联交易协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次签署框架协议涉及的交易为日常关联交易，系基于北京同仁堂股份有 限公司（以下简称公司或本公司）之控股子公司北京同仁堂科技发展股份有限公 司（以下简称同仁堂科技）日常生产经营需要，本次关联交易定价公允，未损害 公司及中小股东的利益，公司不会因本次关联交易对关联方形成依赖。 一、日常关联交易基本情况 （一） 日常关联交易履行的审议程序 基于日常生产经营需要，公司控股子公司同仁堂科技拟与中国北京同仁堂（集 团）有限责任公司（以下简称同仁堂集团）就日常关联交易签署《采购框架性协 议》和《销售框架性协议》，协议期限均为三年。 在协议期限（2026-2028 年）内，同仁堂科技及其子公司预计与同仁堂集团 （含同仁堂集团控制的除本公司及本公司控股子公司以外的其他法人或其他组织， 下同）发生的日常关联采购、销售上限额度详见本公告"一、日常关联交 ...

北京同仁堂股份有限公司 证券代码：600085 证券简称：同仁堂 公告编号：2025-032 第十届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 北京同仁堂股份有限公司（以下简称公司或本公司）第十届董事会第十五次 会议于 2025 年 9 月 29 日在公司会议室以现场结合通讯会议方式召开。本次会议 通知已提前送达全体董事，与会各位董事均已知悉与本次会议所议事项的相关必 要信息。本次董事会会议应出席董事 10 人，实际出席 10 人。公司部分高级管理 人员列席了本次会议。会议由董事长张朝华女士主持，会议的召开和表决程序符 合《中华人民共和国公司法》及《北京同仁堂股份有限公司章程》（以下简称《公 司章程》）的有关规定。 二、会议审议情况 （一） 审议通过了《关于控股子公司与关联方签订采购框架性协议及额度预 计的议案》 公司控股子公司北京同仁堂科技发展股份有限公司（以下简称同仁堂科技） 拟与中国北京同仁堂（集团）有限责任公司（以下简称同仁堂集团）就日常关联 交易签署《采购框架性协议》 ...

（记者 曾健辉） 2025年1至6月份，同仁堂的营业收入构成为：医药工业占比67.17%，医药商业占比61.98%，其他业务 占比0.55%，其他占比0.45%，抵销占比-30.16%。 每经头条（nbdtoutiao）——农夫大战怡宝，抢到更多蛋糕的却是宗馥莉！农夫绿瓶上市后，怡宝上 演"滑铁卢"：市占率大跌近5个百分点 截至发稿，同仁堂市值为469亿元。 每经AI快讯，同仁堂（SH 600085，收盘价：34.21元）9月29日晚间发布公告称，公司第十届第十五次 董事会会议于2025年9月29日在公司会议室以现场结合通讯会议方式召开。会议审议了《关于控股子公 司与关联方签订采购框架性协议及额度预计的议案》等文件。 ...

Group 1 - The 2025 China International Service Trade Fair is being held in Beijing, focusing on the theme "Intelligent Leadership for a Healthy Life" [1] - Traditional Chinese medicine (TCM) brands showcased innovative concepts, digital services, and health products, attracting significant attention [1] - Beijing Tongrentang's presentation included international development efforts and new product launches, aiming to transform TCM from a "Chinese product" to a "globally shared health solution" [1] Group 2 - The fair features a health and wellness service exhibition, highlighting the advancements in TCM and its integration into global health strategies [1] - A concurrent TCM conference was held, facilitating cross-border collaborations and the release of new products [1] - The event emphasizes the importance of TCM in the global health landscape and its potential for international market expansion [1]